Navigation Links
Potential new eye tumor treatment discovered
Date:8/4/2011

Baltimore, MD New research from a team including several Carnegie scientists demonstrates that a specific small segment of RNA could play a key role in the growth of a type of malignant childhood eye tumor called retinoblastoma. The tumor is associated with mutations of a protein called Rb, or retinoblastoma protein. Dysfunctional Rb is also involved with other types of cancers, including lung, brain, breast and bone. Their work, which will be the cover story of the August 15th issue of Genes & Development, could result in a new therapeutic target for treating this rare form of cancer and potentially other cancers as well.

MicroRNAs are a short, single strands of genetic material that bind to longer strands of messenger RNA--which is the courier that brings the genetic code from the DNA in the nucleus to the cell's ribosome, where it is translated into protein. This binding activity allows microRNAs to silence the expression of select genes in a targeted manner. Abnormal versions of microRNAs have been implicated in the growth of several types of cancer.

The paper from Carnegie's Karina Conkrite, Maggie Sundby and David MacPherson--as well as authors from other institutionsfocuses on a cluster of microRNAs called miR-17~92. Recent research has shown that aberrant versions of this cluster are involved in preventing pre-cancerous cells from dying and allowing them to proliferate into tumors. Previous work has shown that miR-17~92 can be involved in the survival of lymphoma and leukemia cells by reducing the levels of a tumor-suppressing protein called PTEN.

The team's new research shows that miR-17~92 can also be involved in retinoblastoma, although it does not act in the same way, via the PTEN protein, as it does in other types of cancers. Rather, miR-17~92 acts to help cells that lack the tumor-suppressing Rb protein to proliferate.

First the team demonstrated that miR-17~92 is expressed in higher-than-usual quantities in all human retinoblastomas examined and in some mouse retinoblastomas. The authors engineered mice to express high levels of miR-17~92 in their retinas. When coupled with inactivation of Rb family members, expression of miR-17~92 led to extremely rapid and aggressive retinoblastoma. Then they showed that this abundance of miR-17~92 acts to suppress an inhibitor of proliferation, called p21Cip1, which is supposed to compensate for the loss of Rb.

"These findings which show that miR-17~92 overcomes the cell's attempts to compensate for the loss of Rbcould be similar in other types of cancers," MacPherson said. "This microRNA cluster could represent a new therapeutic target for treating tumors caused by Rb deficiency."


'/>"/>

Contact: David MacPherson
macpherson@ciwemb.edu
410-246-3084
Carnegie Institution
Source:Eurekalert

Related biology news :

1. Dissecting the genomes of crop plants to improve breeding potential
2. Researchers find potential key for unlocking biomass energy
3. Neural stem progenitor cell transplantation’s potential to aid spinal cord injury tested
4. Scientists devise way to sort brain cells for potential transplants
5. BUSM study identifies new potential approaches to treat myelofibrosis
6. Potential impact of cinnamon on multiple sclerosis studied
7. UF review of resveratrol studies confirms potential health boost
8. U-M researchers find potential new way to fight sepsis
9. Researchers discover potential cause of chronic painful skin
10. Adjuvant combo shows potential for universal influenza vaccine
11. Potential treatment for deadly E. coli disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... Q BioMed Inc. (OTCQB: QBIO), a ... featured presenter at the 5th Annual Marcum MicroCap Conference on ... at the Grand Hyatt Hotel. The ... CEO, is scheduled to begin at 11a.m ET in the ... recent developments and outline milestones for the balance of 2016 ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... manufacturing company, today announced several positive developments that position the Company for the ... result of the transaction, Craig F. Kinghorn has been appointed Chairman of the ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... a Thai delegation at BIO 2016 in San Francisco. Located at booth number ... be available to answer questions and discuss the Thai biotechnology and life sciences ...
(Date:5/25/2016)... ... May 25, 2016 , ... The American ... the Office of the National Coordinator for Health IT (ONC) outlining a measurement ... relevant data were available when and where it was needed. The organization of ...
Breaking Biology Technology: